Department of Cardiology
Dr. Abhishek Srivastava is currently working at National Cancer Institute at National Institutes of Health (NIH) where his translational research involves the development of new immunotherapy strategies against advanced cancers. He received his PhD from University of Louisville, School of Medicine, USA. Dr. Srivastava also brings the pharmaceutical industry experience as he worked as Research Investigator to support the innovative immuno-oncology drug discovery pipeline for Bristol-Myers Squibb. Dr. Srivastava authored 30 plus research articles which include abstracts, book chapter and expert opinions.
Dr. Abhishek Srivastava’s main research interest is the utilization of immune-modulating agents for the improvement of current tumor-specific vaccines and adoptive T cell therapy (ACT). His research primarily focus on the application of multiple cellular and molecular approaches including preclinical in vitro experimentation, in vivo murine models, and innovative human clinical trials to evaluate and explore the mechanism of these immunomodulators as an effective immunotherapy for advanced cancers.